Van Vu K, Mitchell P, Detaram HD, et al. - In patients (n = 547) with neovascular age‐related macular degeneration (nAMD) who presented for anti‐vascular endothelial growth factor therapy, researchers explored the prevalence and risk factors of depressive symptoms in this clinic‐based cohort. To determine the presence of depressive symptoms, the Centre of Epidemiological Studies Depression 10‐point scale (CES‐D‐10) and Mental Health Index (MHI) component of the 36‐item Short Form Survey were given to patients with nAMD who presented for treatment. As per the CES‐D‐10 and MHI scales, the prevalence of depressive symptoms was 42.04% and 31.78%, respectively. Among nAMD patients presenting for treatment, a high prevalence of depressive symptoms was noted. Increased chances of depressive symptoms were associated with poorer self‐rated health, activities of daily living impairment, and decreased visual function.